tiprankstipranks
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Ownership - Who Owns Intra-Cellular Therapies?

853 Followers

Intra-Cellular Therapies (ITCI) Ownership Overview

31.90%33.73%14.09%20.28%
31.90% Insiders
14.09% Other Institutional Investors
20.28% Public Companies and
Individual Investors
The ownership structure of Intra-Cellular Therapies (ITCI) stock is a mix of institutional, retail and individual investors. Approximately 47.82% of the company’s stock is owned by Institutional Investors, 31.90% is owned by Insiders and 20.28% is owned by Public Companies and Individual Investors.
The ownership structure of Intra-Cellular Therapies (ITCI) stock is a mix of institutional, retail and individual investors. Approximately 47.82% of the company’s stock is owned by Institutional Investors, 31.90% is owned by Insiders and 20.28% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 25, 2024
Rory Riggs
Director
xxxxxxxxxxxxx
$337193
Feb 28, 2024
xxxxxxxxxxxxx
$1458650
Feb 27, 2024
Joel Marcus
Director
xxxxxxxxxxxxx
$1808253
Nov 08, 2023
Mark Neumann
Evp & Cco
xxxxxxxxxxxxx
$2357990

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024
xxxxxxxxxxxxx
$149956
Mar 31, 2024
xxxxxxxxxxxxx
$253272
Mar 31, 2024
xxxxxxxxxxxxx
$1183804
Mar 31, 2024
xxxxxxxxxxxxx
$1557000

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
9,078,114Institution8.60%679,587,614
7,922,822Institution7.50%593,102,455
5,736,643Insider5.43%429,445,095
4,645,672Institution4.40%347,775,006
3,638,389Insider3.45%272,369,801
3,596,205Insider3.41%269,211,906
3,596,205Insider3.41%269,211,906
2,978,299Institution2.82%222,955,463
2,230,765Institution2.11%166,995,068
1,193,732Institution1.13%89,362,778

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,922,822Institution7.50%593,102,455
4,645,672Institution4.40%347,775,006
2,230,765Institution2.11%166,995,068
1,062,355Institution1.01%79,527,895
1,055,732Institution1.00%79,032,098
1,048,130Institution0.99%78,463,012
954,007Institution0.90%71,416,964
941,088Institution0.89%70,449,848
921,771Institution0.87%69,003,777
910,528Institution0.86%68,162,126

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,207,337Institution3.04%219,670,511
2,521,011Institution2.39%172,664,043
1,486,704Institution1.41%101,824,357
1,416,466Institution1.34%97,013,756
729,702Institution0.69%54,625,492
565,673Institution0.54%42,346,281
489,439Institution0.46%36,639,404
464,816Institution0.44%34,833,311
374,534Institution0.35%28,037,615
322,185Institution0.31%24,118,769

FAQ

Who Owns Intra-Cellular Therapies (ITCI)?
According to the latest TipRanks data, approximately 14.09% of the company's stock is held by institutional investors, 31.90% is held by insiders, and 20.28% is held by retail investors.
    What percentage of Intra-Cellular Therapies (ITCI) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 14.09% of Intra-Cellular Therapies (ITCI) stock is held by institutional investors.
      What percentage of Intra-Cellular Therapies (ITCI) stock is held by retail investors?
      According to the latest TipRanks data, approximately 20.28% of Intra-Cellular Therapies (ITCI) stock is held by retail investors.
        Who owns the most shares of Intra-Cellular Therapies (ITCI)?
        Vanguard owns the most shares of Intra-Cellular Therapies (ITCI).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis